Biomedical Engineering Reference
In-Depth Information
S. No.
Developer/
Partner
Product Details
Clinical Status as
on Dec. 2009
Drug Target
Indication
Route of
Delivery
A. Aptamers
1.
Ophthotech
Corporation
ARC1905
Phase I
Anti-C5
AMD
Intravenous
E10030
Phase I
PDGF
AMD
Intravitreal
injections
2.
Eyetech Pharmaceuticals/
Pfizer
Pegaptanib
sodium
(Macugen)
Marketed (FDA
approved)
VEGF
AMD
Intravitreal
injections
Eyetech
Pharmaceuticals
EYE001
Phase II/Phase III,
completed in 2002
VEGF
Macular degeneration,
choroidal neovascularization
Intravitreal
injections
3.
National Heart, Lung, and
Blood Institute (NHLBI)
REG1
Phase I
Dual effect of antifactor
IX and antidrug
Anticoagulation
Intravenous
4.
Noxxon Pharma AG
NOX-E36
Phase I
Monocyte chemotactic
protein-1 (MCP-1)
Chronic inflammatory diseases,
Type 2 diabetes mellitus,
systemic lupus erythematosus
Intravenous and
subcutaneous
injection
Noxxon Pharma AG;
German Federal Ministry
of Education and Research
NOX-A12
Phase I
Inhibitor of stromal cell-
derived factor-1 (SDF-1)
Autologous stem cell
transplantation
Intravitreal
injections
Archemix Corp.
ARC1779
Phase II
vWF (Von Willebrand
factor)
Platelet disorders
Intravenous
infusion
B. Ribozymes
1.
Johnson & Johnson
Pharmaceutical Research &
Development, L.L.C./
Tibotec Pharmaceutical
Limited
OZ1
Phase II
Anti-HIV-1 gene
HIV infections
Not available
2.
Jonsson Comprehensive
Cancer Center
National Cancer Institute (NCI)
RPI.4610
Phase II
Anti-FLT-1
Kidney cancer
Subcutaneous
injection
Search WWH ::
Custom Search